LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Women's health doctor Ravina Bhanot, from Zonas Fertility, told LADbible: "Hair loss while taking Mounjaro is a common side ...

One person using Mounjaro revealed they had a peculiar ‘magic mushroom’ sensation when starting the medication in a discussion about side effects on Reddit ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

In India's rapidly growing anti-obesity drug landscape, Mounjaro (tirzepatide), launched by Eli Lilly in March 2025, is ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.

The demand for weight-loss medications is rapidly increasing in India, with competitors Eli Lilly and Novo Nordisk vying for ...